Answers are grounded in this paper and cite their sources.
Novel trimerization motif improves stability of vaccines and therapeutic proteins, suggesting enhanced antibody responses.
Abstract Trimerization motifs play pivotal roles in structural biology and therapeutic protein engineering. Here, we engineered a novel short trimerization motif (rFd1303) derived from the Reoviridae family reovirus σ1 protein. Compared with the widely used T4-Foldon, the rFd1303 enhanced thermal stability and increased recombinant protein yields. The rFd1303-fused immunogens of SARS-CoV-2 spike and influenza hemagglutinin elicited antibody responses comparable to T4-Foldon-fused controls in murine models. Leveraging the new tag, we engineered the trimeric ACE2-Ig (TriACE2-Ig), which exhibits exceptional stability (room-temperature storage for 30 days) and broad neutralization against multiple SARS-CoV-2 variants (average IC₅₀ of 2.9 ng/mL), showing a 20.9-fold potency improvement over monomeric ACE2-Ig. In the hamster model challenged with various SARS-CoV-2 variants, our data demonstrated that intranasal TriACE2-Ig administration markedly reduced viral loads, virus-induced body-weight loss, lung pathology, and decreased within-cage virus transmission. These findings highlight rFd1303 as a versatile trimerization platform for vaccine and therapeutic protein development.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: